New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication

Human Gene Therapy

Volumn 13, Issue 14, 2002, Pages 1737-1750

  Hernandez Alcoceba, Ruben ^a   Pihalja, Michael ^a   Qian, Dalong ^a   Clarke, Michael F ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; ONCOLYTIC VIRUS; PROTEIN ADEHE2F; PROTEIN ADEHT2; TELOMERASE; TRANSCRIPTASE; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADENOVIRUS 5; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER GROWTH; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HYPOXIA; MOUSE; NONHUMAN; PROMOTER REGION; VIRUS GENOME; VIRUS REPLICATION; VIRUS TRANSCRIPTION;

ADENOCARCINOMA; ADENOVIRUS E1A PROTEINS; ADENOVIRUS E4 PROTEINS; ADENOVIRUSES, HUMAN; ANIMALS; BREAST NEOPLASMS; CELL HYPOXIA; CYTOPATHOGENIC EFFECT, VIRAL; DNA-BINDING PROTEINS; ESTRADIOL; ESTROGENS; FEMALE; FIBROBLASTS; GENE EXPRESSION REGULATION, VIRAL; GENE THERAPY; GENES, SYNTHETIC; GENETIC VECTORS; HELA CELLS; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; NEOPLASMS, HORMONE-DEPENDENT; PROMOTER REGIONS (GENETICS); RECEPTORS, ESTROGEN; TAMOXIFEN; TELOMERASE; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR CELLS, CULTURED; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ADENOVIRIDAE; ANIMALIA; HUMAN ADENOVIRUS; HUMAN ADENOVIRUS TYPE 5;

EID: 0036399291     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/104303402760293574     Document Type: Article

References (56)

1. Adachi, Y., Reynolds, P.N., Yamamoto, M., Wang, M., Takayama, K., Matsubara, S., Muramatsu, T., and Curiel, D.T. (2001). A Midkine promoter-based conditionally replicative adenovirus for treatment of pediatric solid tumors and bone marrow tumor purging. Cancer Res. 61, 7882-7888.
2. Alemany, R., Balague, C., and Curiel, C.T. (2000). Replicative adenoviruses for cancer therapy. Nat. Biotechnol. 18, 723-727.
3. Biederer, C., Ries, S., Brandts, C.H., and McCormick, F. (2002). Replication-selective viruses for cancer therapy. J. Mol. Med. 80, 163-175.
4. Bischoff, J., Kirn, D., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J.A., Sampson-Johannes, A., Fattaey, A., and McCormick, F. (1996). An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373-376.
5. Bos, R., Zhong, H., Hanrahan, C.F., Mommers, E.C.M., Semenza, G.L., Pinedo, H.M., Abeloff, M.D., Simons, J.W., Van Diest, P.J., and Van Der Wall, E. (2001). Levels of hypoxia-inducible factor 1α during breast carcinogenesis. J. Natl. Cancer Inst. 93, 309-314.
6. Branton, P.E., and Roopchand, D.E. (2001). The role of adenovirus E4orf4 protein in viral replication and cell killing. Oncogene 20, 7855-7865.
7. Brugger, W., Buhring, H.J., Grunebach, F., Vogel, W., Kaul, S., Muller, R., Brummendorf, T.H., Ziegler, B.L., Rappold, I., Brossart, P., Scheding, S., and Kanz, L. (1999). Expression of MUC-1 epitopes on normal bone marrow: Implications for the detection of micrometastatic tumor cells. J. Clin. Oncol. 17, 1535-1544.
8. Dachs, G.U., Patterson, A.V., Firth, J.D., Ratcliffe, P.J., Townsend, K.M., Stratford, I.J., and Harris, A.L. (1997). Targeting gene expression to hypoxic tumor cells. Nat. Med. 3, 515-520.
9. Doronin, K., Kuppuswamy, M., Toth, K., Tollefson, A.E., Krajcsi, P., Krougliak, V., and Wold, W.S.M. (2001). Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy. J. Virol. 75, 3314-3324.
10. Ekena, K., Katzenellenbogen, J.A., and Katzenellenbogen, B.S. (1998). Determinants of ligand specificity of estrogen receptor-α: Estrogen versus androgen discrimination. J. Biol. Chem. 273, 693-699.
11. Falgout, B., and Ketner, G. (1987). Adenovirus early region 4 is required for efficient virus particle assembly. J. Virol. 61, 3759-3768.
12. Flint, J., and Shenk, T. (1997). Viral transactivating proteins. Annu. Rev. Genet. 31, 177-212.
13. Fuerer, C., and Iggo, R. (2002). Adenoviruses with Tcf binding sites in multiple early promoters show enhanced selectivity for tumour cells with constitutive activation of the wnt signalling pathway. Gene Ther. 9, 270-281.
14. Fueyo, J., Gomez-Manzano, C., Alemany, R., Lee, P.S., Mcdonnell, T.J., Mitlianga, P., Shi, Y.X., Levin, V.A., Yung, W.K., and Kyritsis, A.P. (2000). A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19, 2-12.
15. Good, L., Dimri, G.P., Campisi, J., and Chen, K.Y. (1996). Regulation of dihydrofolate reductase gene expression and E2F components in human diploid fibroblasts during growth and senescence. J. Cell. Physiol. 168, 580-588.
16. Greider, C.W. (1996). Telomere length regulation. Annu Rev. Biochem. 65, 337-365.
17. Halbert, D.N., Cutt, J.R., and Shenk, T. (1985). Adenovirus early region 4 encodes functions required for efficient DNA replication, late gene expression, and host cell shutoff. J. Virol. 56, 250-257.
18. Hallenbeck, P.L., Chang, Y., Hay, C., Golightly, D., Stewart, D., Lin, J., Phipps, S., and Chiang, Y.L. (1999). A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum. Gene Ther. 10, 1721-1733.
19. Harle-Bachor, C., and Boukamp, P. (1996). Telomerase activity in the regenerative basal layer of the epidermis in human skin and in immortal and carcinoma-derived skin keratinocytes. Proc. Natl. Acad. Sci. U.S.A. 93, 6476-6481.
20. Heise, C., Hermiston, T., Johnson, L., Brooks, G., Sampson-Johannes, A., Williams, A., Hawkins, L., and Kirn, D. (2000). An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat. Med. 6, 1134-1139.
21. Hernandez-Alcoceba, R., Pihalja, M., Wicha, M.S., and Clarke, M.F. (2000). A novel, conditionally replicative adenovirus for the treatment of breast cancer that allows controlled replication of E1a-deleted adenoviral vectors. Hum. Gene Ther. 11, 2009-2024.
22. Hernandez-Alcoceba, R., Pihalja, M., Nunez, G., and Clarke, M.F. (2001). Evaluation of a new dual-specificity promoter for selective induction of apoptosis in breast cancer cells. Cancer Gene Ther. 8, 298-307.
23. Horikawa, I., Cable, P.L., Afshari, C., and Barrett, J.C. (1999). Cloning and characterization of the promoter region of human telomerase reverse transcriptase gene. Cancer Res. 59, 826-830.
24. Hsiao, K., Mcmahon, S.L., and Farnham, P.J. (1994). Multiple DNA elements are required for the growth regulation of the mouse E2F1 promoter. Genes Dev. 8, 1526-1537.
25. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. U.S.A. 95, 7987-7992.
26. Johnson, D.G., Ohtani, K., and Nevins, J.R. (1994). Autoregulatory control of E2F1 expression in response to positive and negative regulators of cell cycle progression. Genes Dev. 8, 1514-1525.
27. Johnson, L., Shen, A., Boyle, L., Kunich, J., Pandey, K., Lemmon, M., Hermiston, T., Giedlin, M., Mccormick, F., and Fattaey, A. (2002). Selective replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell 1, 325-337.
28. Kirn, D. (2001). Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: What have we learned? Gene Ther. 8, 89-98.
29. Komata, T., Kondo, Y., Kanzawa, T., Hirohata, S., Koga, S., Sumiyoshi, H., Srinivasula, S.M., Barna, B.P., Germano, I.M., Takakura, M., Inoue, M., Alnemri, E.S., Shay, J.W., Kyo, S., and Kondo, S. (2001). Treatment of malignant glioma cells with the transfer of constitutively active caspase-6 using the human telomerase catalytic subunit (human telomerase reverse transcriptase) gene promoter. Cancer Res. 61, 5796-5802.
30. Kruyt, F., and Curiel, D.T. (2002). Toward a new generation of conditionally replicating adenoviruses: Pairing tumor selectivity with maximal oncolysis. Hum. Gene Ther. 13, 485-495.
31. Kurihara, T., Brough, D.E., Kovesdi, I., and Kufe, D.W. (2000). Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC-1 antigen. J. Clin. Invest. 106, 763-771.
32. Laughner, E., Taghavi, P., Chiles, K., Mahon, P.C., and Semenza, G.L. (2001). Her2 (neu) signaling increases the rate of hypoxia-inducible factor 1α (HIF-1α) synthesis: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell. Biol. 21, 3995-4004.
33. Majumdar, A.S., Hughes, D.E., Lichtsteiner, S.P., Wang, Z., Lebkowski, J.S., and Vasserot, A.P. (2001). The telomerase reverse transcriptase promoter drives efficacious tumor suicide gene therapy while preventing hepatotoxicity encountered with constitutive promoters. Gene Ther. 8, 568-578.
34. Matsubara, S., Wada, Y., Gardner, T.A., Egawa, M., Park, M., Hsieh, C., Zhau, H.E., Kao, C., Kamidono, S., Gillenwater, J.Y., and Chung, K.W.K. (2001). A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. Cancer Res. 61, 6012-6019.
35. Meyerson, M., Counter, C.M., Eaton, E.N., Ellisen, L.W., Steiner, P., Dickinson-Caddle, S., Ziaugra, L., Beijersbergen, R.L, Davidoff, M.J., Liu, Q., Bacchetti, S., Haber, D.A., and Weinberg, R.A. (1997). HEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization. Cell 90, 785-795.
36. Mizuguchi, H., and Kay, M.A. (1998). Efficient construction of a recombinant adenovirus vector by an improved in vitro ligation method. Hum. Gene Ther. 20, 2577-2583.
37. Moulder, S.L., Yakes, F.M., Muthuswamy, S.K., Bianco, R., Simpson, J.F., and Arteaga, C.L. (2001). Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res. 61, 8887-8895.
38. Neuman, E., Flemington, E.K, Sellers, W.R., and Kaelin, W.G. (1994). Transcription of the E2F-1 gene is rendered cell cycle dependent by E2F DNA-binding sites within its promoter. Mol. Cell. Biol. 14, 6607-6615.
39. Parr, M.J., Manome, Y., Tanaka, T., Wen, P., Kufe, D.W., Kaelin, W.G., and Fine, H.A. (1997). Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nat. Med. 3, 1145-1149.
40. Polager, S., Kalma, Y., Berkovich, E., and Ginsberg, D. (2002). E2Fs up-regulate expression of genes involved in DNA replication, DNA repair and mitosis. Oncogene 21, 437-446.
41. Ramachandra, M., Rahman, A., Zou, A., Vaillancourt, M., Howe, J.A., Antelman, D., Sugarman, B., Demers, G.W., Engler, H., Johnson, D., and Shabram, P. (2001). Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy. Nat. Biotechnol. 19, 1035-1041.
42. ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat. Med. 6, 1128-1133.
43. Sellers, W.R., Rodgers, J.W., and Kaelin, W.G. (1995). A potent transrepression domain in the retinoblastoma protein induces a cell cycle arrest when bound to E2F sites. Proc. Natl. Acad. Sci. U.S.A. 92, 11544-11548.
44. Shenk, T. (1996). Adenoviridae: The viruses and their replication. In Fields Virology. B.N. Fields, D.M. Knipe, and P.M. Howley, eds. (Lippincott-Raven, Philadelphia, PA) pp. 2111-2147.
45. Takakura, M., Kyo, S., Kanaya, T., Hirano, H., Takeda, J., Yutsudo, M., and Inoue, M. (1999). Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res. 59, 551-557.
46. Talks, K.L., Turley, H., Gatter, K.C., Maxwell, P.H., Pugh, C.W., Ratcliffe, P.J., and Harris, A.L. (2000). The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol. 157, 411-421.
47. Tauber, B., and Dobner, T. (2001). Adenovirus early E4 genes in viral oncogenesis. Oncogene 20, 7847-7854.
48. Tsukuda, K., Wiewrodt, R., Molnar-Kimber, K., Jovanovic, V.P., and Amin, K.M. (2002). An E2f-responsive replication-selective adenovirus targeted to the defective cell cycle in cancer cells: Potent antitumoral efficacy but no toxicity to normal cell. Cancer Res. 62, 3438-3447.
49. Ulaner, G.A., Hu, J.F., Vu, T.H., Guidice, L.C., and Hoffman, A.R. (1998). Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternate splicing of hTERT transcripts. Cancer Res. 58, 4168-4172.
50. Valavaara, R. (1997). Reliability of estrogen receptors in predicting response to antiestrogens. Oncology 11, 14-18.
51. Vassaux, G., Hurst, H.C., and Lemoine, N.R. (1999). Insulation of a conditionally expressed transgene in an adenoviral vector. Gene Ther. 6, 1192-1197.
52. Wick, M., Zubov, D., and Hagen, G. (1999). Genomic organization and promoter characterization of the gene encoding the human telomerase reverse transcriptase (hTERT). Gene 232, 97-106.
53. ARF modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53. Cancer Res. 61, 5959-5963.
54. Yu, D., Sakamoto, G.T., and Henderson, D.R. (1999). Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res. 59, 1498-1504.
55. Zhang, A., Zheng, C., Lindvall, C., Hou, M., Ekedahl, J., Lewensohn, R., Yan, Z., Yang, X., Henriksson, M., Blennow, E., Nordenskjold, M., Zetterberg, A., Bjorkholm, M., Gruber, A., and Xu, D. (2000). Frequent amplification of the telomerase reverse transcriptase gene in human tumors. Cancer Res. 60, 6230-6235.
56. Zhong, H., De Marzo, A.M., Laughner, E., Lim, M., Hilton, D.A., Zagzag, D., Buechler, P., Isaacs, W.B., Semenza, G.L., and Simons, J.W. (1999). Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res. 15, 5830-5835.